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Randomized controlled trials (RCTs) are considered the gold standard for determining efficacy and safety of new drugs. Successful randomization addresses known and unknown confounding when assessing a drug's effect among trial patients selected on strict inclusion and exclusion criteria (1) . However, treatment results have been shown on occasion to be much less favorable than expected outside trial populations, often related to differences in age, comorbidity, disease severity, drug compliance, and/or comedication among patients treated in everyday clinical practice (1) Exclusion criteria were largely similar in the LEAD 1-5 trials, and we used only exclusion criteria that were shared in all five trials. When exact information was unavailable in our databases (i.e., BMI and blood pressure), we assumed that patients would be eligible for trial participation.
Routine clinical care liraglutide users frequently had comorbidities that would have made them ineligible for the LEAD 1-5 trials, including "clinically significant cardiovascular disease" (29%) or "other significant disease" (11%) ( Table 1) . Further, 27% had HbA 1c levels outside the values needed for inclusion in the LEAD 1-5 trials, and 37% were on current insulin, another exclusion criterion in the LEAD 1-5 trials. Overall, 73% of all real-world liraglutide users would have been ineligible for any of the LEAD trials ( 
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